Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC.

Schizophr Bull. 2016 Mar;42(2):335-43. doi: 10.1093/schbul/sbv072. Epub 2015 Jun 12.

2.

Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.

Möller HJ, Demyttenaere K, Olausson B, Szamosi J, Wilson E, Hosford D, Dunbar G, Tummala R, Eriksson H.

World J Biol Psychiatry. 2015 Oct;16(7):483-501. doi: 10.3109/15622975.2014.989261. Epub 2015 Jan 20.

PMID:
25602163
3.

Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.

Tummala R, Desai D, Szamosi J, Wilson E, Hosford D, Dunbar G, Eriksson H.

J Clin Psychopharmacol. 2015 Feb;35(1):77-81. doi: 10.1097/JCP.0000000000000269.

PMID:
25514064
4.

Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.

Vieta E, Thase ME, Naber D, D'Souza B, Rancans E, Lepola U, Olausson B, Szamosi J, Wilson E, Hosford D, Dunbar G, Tummala R, Eriksson H.

Eur Neuropsychopharmacol. 2014 Apr;24(4):564-74. doi: 10.1016/j.euroneuro.2013.12.008. Epub 2013 Dec 21.

PMID:
24507016
5.

AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.

Potter AS, Dunbar G, Mazzulla E, Hosford D, Newhouse PA.

Biol Psychiatry. 2014 Feb 1;75(3):207-14. doi: 10.1016/j.biopsych.2013.06.002. Epub 2013 Jul 12.

PMID:
23856296
6.

Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy.

Sasportas LS, Hosford DN, Sodini MA, Waters DJ, Zambricki EA, Barral JK, Graves EE, Brinton TJ, Yock PG, Le QT, Sirjani D.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jul;116(1):e37-51. doi: 10.1016/j.oooo.2013.02.017. Epub 2013 May 3. Review.

7.

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA.

Neuropsychopharmacology. 2013 May;38(6):968-75. doi: 10.1038/npp.2012.259. Epub 2012 Dec 18.

8.

Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study.

Kasperaviciūte D, Catarino CB, Heinzen EL, Depondt C, Cavalleri GL, Caboclo LO, Tate SK, Jamnadas-Khoda J, Chinthapalli K, Clayton LM, Shianna KV, Radtke RA, Mikati MA, Gallentine WB, Husain AM, Alhusaini S, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Heuser K, Amos L, Ortega M, Zumsteg D, Wieser HG, Steinhoff BJ, Krämer G, Hansen J, Dorn T, Kantanen AM, Gjerstad L, Peuralinna T, Hernandez DG, Eriksson KJ, Kälviäinen RK, Doherty CP, Wood NW, Pandolfo M, Duncan JS, Sander JW, Delanty N, Goldstein DB, Sisodiya SM.

Brain. 2010 Jul;133(Pt 7):2136-47. doi: 10.1093/brain/awq130. Epub 2010 Jun 3.

9.

Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes.

Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, Walley NM, Nicoletti P, Ge D, Catarino CB, Duncan JS, Kasperaviciūte D, Tate SK, Caboclo LO, Sander JW, Clayton L, Linney KN, Shianna KV, Gumbs CE, Smith J, Cronin KD, Maia JM, Doherty CP, Pandolfo M, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Kälviäinen R, Eriksson K, Kantanen AM, Dorn T, Hansen J, Krämer G, Steinhoff BJ, Wieser HG, Zumsteg D, Ortega M, Wood NW, Huxley-Jones J, Mikati M, Gallentine WB, Husain AM, Buckley PG, Stallings RL, Podgoreanu MV, Delanty N, Sisodiya SM, Goldstein DB.

Am J Hum Genet. 2010 May 14;86(5):707-18. doi: 10.1016/j.ajhg.2010.03.018. Epub 2010 Apr 15.

10.

The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.

Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, Jones NA, Nock CM, Roses AD, Saunders AM, Skehel JM, Smith MA, Cutler P.

Biomarkers. 2008 Sep;13(6):618-36. doi: 10.1080/13547500802445199 .

PMID:
18830857
11.

Partnership between academia and industry for drug discovery in Alzheimer's disease.

Ivinson AJ, Lane R, May PC, Hosford DA, Carrillo MC, Siemers ER.

Alzheimers Dement. 2008 Mar;4(2):80-8. doi: 10.1016/j.jalz.2008.02.004. Erratum in: Alzheimers Dement. 2008 May;4(3):230-1.

PMID:
18631952
12.

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

Irizarry MC, Webb DJ, Bains C, Barrett SJ, Lai RY, Laroche JP, Hosford D, Maher-Edwards G, Weil JG.

J Alzheimers Dis. 2008 Jul;14(3):301-11.

PMID:
18599956
13.

Two novel alleles of tottering with distinct Ca(v)2.1 calcium channel neuropathologies.

Miki T, Zwingman TA, Wakamori M, Lutz CM, Cook SA, Hosford DA, Herrup K, Fletcher CF, Mori Y, Frankel WN, Letts VA.

Neuroscience. 2008 Jul 31;155(1):31-44. doi: 10.1016/j.neuroscience.2008.05.028. Epub 2008 Jul 1.

14.

Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease.

Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD.

Arch Neurol. 2008 Jan;65(1):45-53. Epub 2007 Nov 12.

PMID:
17998437
15.

An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases.

O'Dushlaine CT, Dolan C, Weale ME, Stanton A, Croke DT, Kalviainen R, Eriksson K, Kantanen AM, Gibson RA, Hosford D, Sisodiya SM, Gill M, Corvin AP, Morris DW, Delanty N, Cavalleri GL.

Eur J Hum Genet. 2008 Feb;16(2):176-83. Epub 2007 Oct 31.

16.

Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study.

Cavalleri GL, Weale ME, Shianna KV, Singh R, Lynch JM, Grinton B, Szoeke C, Murphy K, Kinirons P, O'Rourke D, Ge D, Depondt C, Claeys KG, Pandolfo M, Gumbs C, Walley N, McNamara J, Mulley JC, Linney KN, Sheffield LJ, Radtke RA, Tate SK, Chissoe SL, Gibson RA, Hosford D, Stanton A, Graves TD, Hanna MG, Eriksson K, Kantanen AM, Kalviainen R, O'Brien TJ, Sander JW, Duncan JS, Scheffer IE, Berkovic SF, Wood NW, Doherty CP, Delanty N, Sisodiya SM, Goldstein DB.

Lancet Neurol. 2007 Nov;6(11):970-80.

PMID:
17913586
17.

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD; Rosiglitazone in Alzheimer's Disease Study Group.

Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54. Epub 2006 Jan 31.

PMID:
16446752
18.

Pharmacogenetics to predict drug-related adverse events.

Hosford DA, Lai EH, Riley JH, Xu CF, Danoff TM, Roses AD.

Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:9-12. Review.

PMID:
15209398
19.

Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine.

McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ, Hewett DR, Peroutka SJ, Griffiths LR, Boyd PR, Lea RA, Bhatti SM, Hosking LK, Hood CM, Jones KW, Handley AR, Rallan R, Lewis KF, Yeo AJ, Williams PM, Priest RC, Khan P, Donnelly C, Lumsden SM, O'Sullivan J, See CG, Smart DH, Shaw-Hawkins S, Patel J, Langrish TC, Feniuk W, Knowles RG, Thomas M, Libri V, Montgomery DS, Manasco PK, Xu CF, Dykes C, Humphrey PP, Roses AD, Purvis IJ.

Genomics. 2001 Dec;78(3):135-49. Erratum in: Genomics 2002 Feb;79(2):271.

PMID:
11735220
20.

Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity.

Fletcher CF, Tottene A, Lennon VA, Wilson SM, Dubel SJ, Paylor R, Hosford DA, Tessarollo L, McEnery MW, Pietrobon D, Copeland NG, Jenkins NA.

FASEB J. 2001 May;15(7):1288-90. No abstract available.

PMID:
11344116
21.

Studies of the lethargic (lh/lh) mouse model of absence seizures: regulatory mechanisms and identification of the lh gene.

Hosford DA, Lin FH, Wang Y, Caddick SJ, Rees M, Parkinson NJ, Barclay J, Cox RD, Gardiner RM, Hosford DA, Denton P, Wang Y, Seldin MF, Chen B.

Adv Neurol. 1999;79:239-52. Review.

PMID:
10514818
22.

Animal models of nonconvulsive status epilepticus.

Hosford DA.

J Clin Neurophysiol. 1999 Jul;16(4):306-13; discussion 353. Review.

PMID:
10478703
23.
24.

Glutamate decarboxylase isoforms in thalamic nuclei in lethargic mouse model of absence seizures.

Lin FH, Lin S, Wang Y, Hosford DA.

Brain Res Mol Brain Res. 1999 Jul 23;71(1):127-30.

PMID:
10407195
26.

Excitatory but not inhibitory synaptic transmission is reduced in lethargic (Cacnb4(lh)) and tottering (Cacna1atg) mouse thalami.

Caddick SJ, Wang C, Fletcher CF, Jenkins NA, Copeland NG, Hosford DA.

J Neurophysiol. 1999 May;81(5):2066-74.

27.

Migratory leptomeningeal inflammation with relapsing polychondritis.

Kothare SV, Chu CC, VanLandingham K, Richards KC, Hosford DA, Radtke RA.

Neurology. 1998 Aug;51(2):614-7.

PMID:
9710051
28.
29.

Generalized epilepsies: emerging insights into cellular and genetic mechanisms.

Hosford DA, Caddick SJ, Lin FH.

Curr Opin Neurol. 1997 Apr;10(2):115-20. Review.

PMID:
9147002
31.

The role of GABAB mechanisms in animal models of absence seizures.

Caddick SJ, Hosford DA.

Mol Neurobiol. 1996 Aug;13(1):23-32. Review.

PMID:
8892334
32.
33.

Modulation of swimming in the lamprey, Petromyzon marinus, by serotonergic and dopaminergic drugs.

Kemnitz CP, Strauss TR, Hosford DM, Buchanan JT.

Neurosci Lett. 1995 Dec 8;201(2):115-8.

PMID:
8848231
34.

GABAB receptor-mediated effects in synaptosomes of lethargic (lh/lh) mice.

Lin FH, Wang Y, Lin S, Cao Z, Hosford DA.

J Neurochem. 1995 Nov;65(5):2087-95.

PMID:
7595494
35.

Neural network of structures in which GABAB receptors regulate absence seizures in the lethargic (lh/lh) mouse model.

Hosford DA, Lin FH, Kraemer DL, Cao Z, Wang Y, Wilson JT Jr.

J Neurosci. 1995 Nov;15(11):7367-76.

36.
37.

Models of primary generalized epilepsy.

Hosford DA.

Curr Opin Neurol. 1995 Apr;8(2):121-5. Review.

PMID:
7620585
38.

Differences in the anatomic distribution of immediate-early gene expression in amygdala and angular bundle kindling development.

Hosford DA, Simonato M, Cao Z, Garcia-Cairasco N, Silver JM, Butler L, Shin C, McNamara JO.

J Neurosci. 1995 Mar;15(3 Pt 2):2513-23.

39.

Receptors for somatostatin and somatostatin analogues in human breast tumors.

Prévost G, Hosford D, Thomas F.

Ann N Y Acad Sci. 1994 Sep 15;733:147-54. Review. No abstract available.

PMID:
7978862
40.

Platelet-activating factor antagonists: scientific background and possible clinical applications.

Koltai M, Guinot P, Hosford D, Braquet PG.

Adv Pharmacol. 1994;28:81-167. Review. No abstract available.

PMID:
8080821
41.

Increased number of GABAB receptors in the lethargic (lh/lh) mouse model of absence epilepsy.

Lin FH, Cao Z, Hosford DA.

Brain Res. 1993 Apr 9;608(1):101-6.

PMID:
8388308
42.

PAF-induced amplification of mediator release in septic shock: prevention or downregulation by PAF antagonists.

Koltai M, Hosford D, Braquet P.

J Lipid Mediat. 1993 Mar-Apr;6(1-3):183-98. Review. No abstract available.

PMID:
8357981
43.

Induction of c-fos mRNA by kindled seizures: complex relationship with neuronal burst firing.

Labiner DM, Butler LS, Cao Z, Hosford DA, Shin C, McNamara JO.

J Neurosci. 1993 Feb;13(2):744-51.

44.

Platelet-activating factor in septic shock.

Koltai M, Hosford D, Braquet PG.

New Horiz. 1993 Feb;1(1):87-95. Review.

PMID:
7922397
45.

The role of GABAB receptor activation in absence seizures of lethargic (lh/lh) mice.

Hosford DA, Clark S, Cao Z, Wilson WA Jr, Lin FH, Morrisett RA, Huin A.

Science. 1992 Jul 17;257(5068):398-401.

PMID:
1321503
46.

Role of PAF and cytokines in microvascular tissue injury.

Koltai M, Hosford D, Braquet P.

J Lab Clin Med. 1992 May;119(5):461-6. No abstract available.

PMID:
1316420
47.

PAF receptor and "Cache-oreilles" effect. Simple PAF antagonists.

Lamotte-Brasseur J, Heymans F, Dive G, Lamouri A, Batt JP, Redeuilh C, Hosford D, Braquet P, Godfroid JJ.

Lipids. 1991 Dec;26(12):1167-71.

PMID:
1668113
48.
49.

Differential expression of immediate early genes in the hippocampus in the kindling model of epilepsy.

Simonato M, Hosford DA, Labiner DM, Shin C, Mansbach HH, McNamara JO.

Brain Res Mol Brain Res. 1991 Sep;11(2):115-24.

PMID:
1661808
50.

PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Koltai M, Hosford D, Guinot P, Esanu A, Braquet P.

Drugs. 1991 Aug;42(2):174-204. Review. No abstract available.

PMID:
1717219

Supplemental Content

Loading ...
Support Center